- Home
- LRMR vs NCZ Comparison
LRMR vs NCZ Comparison
Compare LRMR & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- NCZ
- Stock Information
- Founded
- LRMR N/A
- NCZ 2003
- Country
- LRMR United States
- NCZ United States
- Employees
- LRMR N/A
- NCZ N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- LRMR Health Care
- NCZ Finance
- Exchange
- LRMR Nasdaq
- NCZ Nasdaq
- Market Cap
- LRMR 191.4M
- NCZ 228.3M
- IPO Year
- LRMR N/A
- NCZ N/A
- Fundamental
- Price
- LRMR $3.09
- NCZ $12.85
- Analyst Decision
- LRMR Strong Buy
- NCZ
- Analyst Count
- LRMR 7
- NCZ 0
- Target Price
- LRMR $17.86
- NCZ N/A
- AVG Volume (30 Days)
- LRMR 1.4M
- NCZ 533.0K
- Earning Date
- LRMR 08-06-2025
- NCZ 01-01-0001
- Dividend Yield
- LRMR N/A
- NCZ 12.16%
- EPS Growth
- LRMR N/A
- NCZ N/A
- EPS
- LRMR N/A
- NCZ N/A
- Revenue
- LRMR N/A
- NCZ N/A
- Revenue This Year
- LRMR N/A
- NCZ N/A
- Revenue Next Year
- LRMR N/A
- NCZ N/A
- P/E Ratio
- LRMR N/A
- NCZ N/A
- Revenue Growth
- LRMR N/A
- NCZ N/A
- 52 Week Low
- LRMR $1.61
- NCZ $2.50
- 52 Week High
- LRMR $11.20
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- LRMR 60.78
- NCZ 72.30
- Support Level
- LRMR $2.81
- NCZ $12.49
- Resistance Level
- LRMR $3.19
- NCZ $12.95
- Average True Range (ATR)
- LRMR 0.30
- NCZ 0.15
- MACD
- LRMR 0.01
- NCZ 0.04
- Stochastic Oscillator
- LRMR 82.43
- NCZ 87.50
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.